CLPP
ATP-dependent Clp protease proteolytic subunit, mitochondrial
As of the edition of 20 October 2026, CLPP (ATP-dependent Clp protease proteolytic subunit, mitochondrial, UniProt Q16740) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16740
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 34
- Disease areas
- Cancer; Nervous system; Blood and lymph; Immune system; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Digestive system
- Registered trials of its drugs
- 34
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dordaviprone | Marketed | Phase 3 | Ends 2032 |
| ONC-206 | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Chimerix | Route B |
The other 1 company at CLPP
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at CLPP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.